


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:


Listing of Claims:

1-37 (Canceled)

38. (Currently Amended) A method for treating an interleukin-12 overproduction-related disorder, comprising administering to a subject in need thereof an effective amount of the compound of formula (I):



wherein



each of R<sub>2</sub> and R<sub>4</sub>, independently, is R<sup>c</sup>, halogen, nitro, cyano, isothionitro, SR<sup>c</sup>, or OR<sup>c</sup>;  
 or R<sub>2</sub> and R<sub>4</sub>, taken together, is carbonyl[.];

R<sub>3</sub> is R<sup>c</sup>, alkenyl, alkynyl, OR<sup>c</sup>, OC(O)R<sup>c</sup>, SO<sub>2</sub>R<sup>c</sup>, S(O)R<sup>c</sup>, S(O<sub>2</sub>)NR<sup>c</sup>R<sup>d</sup>, SR<sup>c</sup>, NR<sup>c</sup>R<sup>d</sup>, NR<sup>c</sup>COR<sup>d</sup>, NR<sup>c</sup>C(O)OR<sup>d</sup>, NR<sup>c</sup>C(O)NR<sup>c</sup>R<sup>d</sup>, NR<sup>c</sup>SO<sub>2</sub>R<sup>d</sup>, COR<sup>c</sup>, C(O)OR<sup>c</sup>, or C(O)NR<sup>c</sup>R<sup>d</sup>;

R<sub>5</sub> is H or alkyl;

n is 0, 1, 2, 3, 4, 5, or 6;

X is O, S, S(O), S(O<sub>2</sub>), or NR<sup>c</sup>;

Y is a covalent bond, CH<sub>2</sub>, C(O), C=N-R<sup>c</sup>, C=N-OR<sup>c</sup>, C=N-SR<sup>c</sup>, O, S, S(O), S(O<sub>2</sub>), or NR<sup>c</sup>;

Z is N or CH;


one of U and V is N, and the other is CR<sup>c</sup>; and

W is O, S, S(O), S(O<sub>2</sub>), NR<sup>c</sup>, or NC(O)R<sup>c</sup>;


in which each of R<sup>a</sup> and R<sup>b</sup>, independently, is H, alkyl, aryl, heteroaryl; and each of R<sup>c</sup> and R<sup>d</sup>, independently, is H, alkyl, aryl, heteroaryl, cyclyl, heterocyclyl, or alkylcarbonyl.

39. (Original) The method of claim 38, wherein the disorder is rheumatoid arthritis, sepsis, Crohn's disease, multiple sclerosis, psoriasis, or insulin-dependent diabetes mellitus.

40. (New) A pharmaceutical composition comprising an effective amount of the compound of formula (I):



wherein



each of R<sub>2</sub> and R<sub>4</sub>, independently, is R<sup>c</sup>, halogen, nitro, cyano, isothionitro, SR<sup>c</sup>, or OR<sup>c</sup>;  
 or R<sub>2</sub> and R<sub>4</sub>, taken together, is carbonyl;

R<sub>3</sub> is R<sup>c</sup>, alkenyl, alkynyl, OR<sup>c</sup>, OC(O)R<sup>c</sup>, SO<sub>2</sub>R<sup>c</sup>, S(O)R<sup>c</sup>, S(O<sub>2</sub>)NR<sup>c</sup>R<sup>d</sup>, SR<sup>c</sup>, NR<sup>c</sup>R<sup>d</sup>, NR<sup>c</sup>COR<sup>d</sup>, NR<sup>c</sup>C(O)OR<sup>d</sup>, NR<sup>c</sup>C(O)NR<sup>c</sup>R<sup>d</sup>, NR<sup>c</sup>SO<sub>2</sub>R<sup>d</sup>, COR<sup>c</sup>, C(O)OR<sup>c</sup>, or C(O)NR<sup>c</sup>R<sup>d</sup>;

R<sub>5</sub> is H or alkyl;

n is 0, 1, 2, 3, 4, 5, or 6;

X is O, S, S(O), S(O<sub>2</sub>), or NR<sup>c</sup>;

Y is a covalent bond, CH<sub>2</sub>, C(O), C=N-R<sup>c</sup>, C=N-OR<sup>c</sup>, C=N-SR<sup>c</sup>, O, S, S(O), S(O<sub>2</sub>), or NR<sup>c</sup>;


Z is N or CH;

one of U and V is N, and the other is CR<sup>c</sup>; and

W is O, S, S(O), S(O<sub>2</sub>), NR<sup>c</sup>, or NC(O)R<sup>c</sup>;

in which each of R<sup>a</sup> and R<sup>b</sup>, independently, is H, alkyl, aryl, heteroaryl; and each of R<sup>c</sup> and R<sup>d</sup>, independently, is H, alkyl, aryl, heteroaryl, cyclyl, heterocyclyl, or alkylcarbonyl; and a pharmaceutically acceptable carrier.

41. (New) The pharmaceutical composition of claim 40, wherein R<sub>1</sub> is



42. (New) The pharmaceutical composition of claim 41, wherein U is N and V is CH.

43. (New) The pharmaceutical composition of claim 41, wherein Z is N and W is O.

44. (New) The pharmaceutical composition of claim 41, wherein X is NR<sup>c</sup>.

45. (New) The pharmaceutical composition of claim 44, wherein R<sup>c</sup> is H, methyl, ethyl, or acetyl.


46. (New) The pharmaceutical composition of claim 41, wherein Y is O or CH<sub>2</sub>, and n is 0, 1, 2, 3, or 4.

47. (New) The pharmaceutical composition of claim 46, wherein R<sub>3</sub> is aryl or heteroaryl.

48. (New) The pharmaceutical composition of claim 47, wherein  $R_3$  is pyridinyl.

49. (New) The pharmaceutical composition of claim 46, wherein  $R_3$  is  $OR^c$ ,  $SR^c$ ,  $C(O)OR^c$ , or  $C(O)NR^cR^d$ .

50. (New) The pharmaceutical composition of claim 46, wherein  $R_3$  is




in which

each of A and A', independently, is O, S, or NH;

each of  $R^e$  and  $R^f$ , independently is H, alkyl, aryl, or heteroaryl; and

m is 1 or 2.

51. (New) The pharmaceutical composition of claim 41, wherein one of  $R^a$  and  $R^b$  is



in which

B is  $NR^i$ , O, or S;

B' is N or  $CR^i$ ;

$R^g$  is H, alkyl, or alkoxy;


$R^h$  is halogen,  $NO_2$ , CN, alkyl, aryl, heteroaryl,  $OR^c$ ,  $OC(O)R^c$ ,  $SO_2R^c$ ,  $S(O)R^c$ ,  $S(O_2)NR^cR^d$ ,  $SR^c$ ,  $NR^cR^d$ ,  $NR^cCOR^d$ ,  $NR^cC(O)OR^d$ ,  $NR^cC(O)NR^cR^d$ ,  $NR^cSO_2R^d$ ,  $COR^c$ ,  $C(O)OR^c$ , or  $C(O)NR^cR^d$ ;

$R^i$  is H, alkyl, or alkylcarbonyl;

p is 0, 1, or 2; and

q is 0, 1, 2, 3, or 4.

52. (New) The pharmaceutical composition of claim 51, wherein one of  $R^a$  and  $R^b$  is



He is reliable in delivering work product to the client on time the other of  $R^a$  and  $R^b$  is H or alkyl.

53 (New) The pharmaceutical composition of claim 52, wherein  $R^g$  is H, methyl, ethyl, propyl, cyclopropyl, methoxy, or ethoxy;  $R^h$  is F, Cl, CN, methyl, methoxy, ethoxy,  $OC(O)CH_3$ ,  $OC(O)C_2H_5$ ,  $C(O)OH$ ,  $C(O)OC_2H_5$ ,  $C(O)NH_2$ ,  $NHC(O)CH_3$ , or  $S(O_2)NH_2$ ;  $R^i$  is H, methyl, ethyl, or acetyl, and q is 0, 1, or 2.

54 (New) The pharmaceutical composition of claim 53, wherein  $R^g$  is methyl or methoxy;  $R^i$  is H; and q is 0.

55 (New) The pharmaceutical composition of claim 53, wherein U is N and V is CH.

56 (New) The pharmaceutical composition of claim 55, wherein Z is N and W is O.

57 (New) The pharmaceutical composition of claim 56, wherein X is  $NR^c$ ; and  $R^c$  is H, methyl, ethyl, or acetyl.

58 (New) The pharmaceutical composition of claim 57, wherein Y is O or  $CH_2$ ; and n is 0, 1, 2, 3, or 4.

59 (New) The pharmaceutical composition of claim 58, wherein  $R_3$  is aryl or heteroaryl.

60 (New) The pharmaceutical composition of claim 59, wherein  $R_3$  is pyridinyl.


61 (New) The pharmaceutical composition of claim 53, wherein Y is O or  $\text{CH}_2$ , and n is 0, 1, 2, 3, or 4.

62 (New) The pharmaceutical composition of claim 61, wherein  $R_3$  is aryl or heteroaryl.

63 (New) The pharmaceutical composition of claim 61, wherein  $R_3$  is pyridinyl.

64 (New) The pharmaceutical composition of claim 40, wherein  $R_1$  is aryl or heteroaryl.

65 (New) The pharmaceutical composition of claim 64, wherein  $R_1$  is



in which

D is O, S, or  $\text{NR}^m$ ;

$R^j$  is benzo, halogen, CN, hydroxyl, alkyl, aryl, heteroaryl, alkoxyl, aryloxy, or heteroaryloxy;

$R^m$  is H, alkyl, or alkylcarbonyl; and

r is 0, 1, or 2.

66 (New) The pharmaceutical composition of claim 65, wherein X is  $\text{NR}^c$ ; and  $R^c$  is H, methyl, ethyl, or acetyl.

67 (New) The pharmaceutical composition of claim 66, wherein U is N and V is CH.

68 (New) The pharmaceutical composition of claim 67, wherein Z is N and W is O.

69 (New) The pharmaceutical composition of claim 68, wherein Y is O or CH<sub>2</sub>; and n is 0, 1, 2, 3, or 4.


70 (New) The pharmaceutical composition of claim 65, wherein Y is O or CH<sub>2</sub>; and n is 0, 1, 2, 3, or 4.

71 (New) The pharmaceutical composition of claim 70, wherein R<sub>3</sub> is aryl or heteroaryl.

72 (New) The pharmaceutical composition of claim 71, wherein R<sub>3</sub> is pyridinyl.

73 (New) The pharmaceutical composition of claim 70, wherein R<sub>3</sub> is OR<sup>c</sup>, SR<sup>c</sup>, C(O)OR<sup>c</sup>, or C(O)NR<sup>c</sup>R<sup>d</sup>.

74 (New) The pharmaceutical composition of claim 70, wherein R<sub>3</sub> is




in which

each of A and A', independently, is O, S, or NH;

each of R<sup>e</sup> and R<sup>f</sup>, independently is H, alkyl, aryl, or heteroaryl; and

m is 1 or 2.

75 (New) The pharmaceutical composition of claim 70, wherein  $R_1$  is



76. (New) The pharmaceutical composition of claim 75, wherein  $R^j$  is methyl, ethyl, propyl, or benzo; and  $r$  is 1 or 2.